AstraZeneca has initiated the recall of its Covid-19 vaccine across the world due to the “high volume of updated vaccines available” since the pandemic.
“As multiple types of COVID-19 vaccines have been developed, the volume of updated vaccines available is high,” the company said, according to a report by news agency Reuters. This has led to a decline in demand for Vaxzevria, which is no longer manufactured or supplied. The company also said it would take the initiative to withdraw the marketing authorizations of the vaccine Vaxzeveria within Europe.
AstraZeneca admitted the risk of side effects in the British High Court
Recently, pharmaceutical giant AstraZeneca admitted in the British High Court that in “very rare cases”, its vaccine can cause blood clotting (thrombocytopenia syndrome), causing a scare in the minds of people taking the vaccine around the world. Has been born.
AstraZeneca Vaxjavaria vaccine, which was also produced by the Serum Institute of India. This vaccine was marketed in India under the name of Covishield.
Demand raised to form medical expert panel to investigate side effects of Covishield vaccine
Last week, an appeal was filed in the Supreme Court seeking to issue a direction to form a medical expert panel to investigate the side effects of the Covishield vaccine. Lawyer Vishal Tiwari said that more than 175 crore doses of Covishield have been given in India.
The petition was filed by lawyer Vishal Tiwari, who also urged the court to issue directions to the Center to set up a vaccine damage payment system for citizens who die as a result of the vaccination drive during the pandemic. Had become seriously disabled.
Decline in sales of Covid-19 vaccine
According to the Telegraph, the company’s application to withdraw the vaccine was made on March 5 and took effect on May 7.
London-listed AstraZeneca made advances in respiratory syncytial virus vaccines and obesity drugs through a series of deals last year as declining COVID-19 vaccine sales slowed the company’s growth.
